CLEAR TRAJECTORY TO CATEGORY LEADERSHIP.
CLEAR TRAJECTORY TO CATEGORY LEADERSHIP.
VIVVIDAE ADVISORY STEWARDSHIP
Great technology doesn't guarantee clinical uptake. Sound, funded, well-run companies still run into roadblocks. Advisory Stewardship puts experienced judgment beside leadership so innovation becomes real-world adoption.
Stewardship, milestone achievement, and a US healthcare market foothold.
We work with leadership on strategy and execution together, because in this market they don't separate. Engagements sit alongside a CEO, a commercial lead, or a board through a defined phase — preparing for new market entry, seamless creation of a US market foothold, moving from early adopters to widespread adoption, or building the position that carries scale.
WHAT WE WORK ON
Market Entry
Which market, which segment, which first customers, on what terms. Your first reference accounts set the evidence base, the price expectation, and your true brand identity. We pressure-test the options to help you make the most informed decisions.
Integration
A product that doesn't fit the workflow, the reimbursement pathway, and the purchasing structure stalls, however strong the clinical case. This is where promising technology quietly loses momentum. We work the operational fit: how it enters the clinic, who pays, who is accountable, and what has to built to support it.
Clinical Adoption
Adoption is earned from clinicians, not sold to them. It takes evidence that answers the questions practitioners actually ask, champions who carry the product inside their own clinic, and a value case that survives review by all stakeholders. We build all three with you.
US Healthcare Market Foothold
Decades of experience navigating the US Healthcare system means you can have an immediate foothold. Hassle free, built to your budget and needs.
HOW WE WORK
Deep experience in the US healthcare market lets us help leadership make the right call at the right time. Much of this job is knowing which decision belongs to which moment, and the pitfalls to avoid.
That judgment comes from operating in this market, not studying it. We've built companies across medical device, diagnostics, therapeutics, software, and biologics, and we've seen these sequences go well and go badly.
We're direct about what we see. We'll tell you when a plan is premature, when the evidence is thinner than the claim, and when a decision is being deferred rather than made.
And we stay hands-on. Where a decision needs work to become real, we do that work or help assemble the team that will.